ZYBERNO
Stock Report
Updated Aug 26, 2026

Biofrontera Inc. (BFRIW)

Healthcare • NASDAQ

$0.03

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
Biofrontera Inc. (BFRIW) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-319.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.97x)
Operating Margin (Operational Efficiency):CRITICAL (-35.1%)
Return on Capital (Capital Efficiency):CRITICAL (-290.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Biofrontera Inc. (BFRIW) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BFRIW generated -$9.32M in Owner Earnings. Capital was deployed as follows: $4.00K invested in capital expenditures. Reinvestment rate: 1.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.03
Market Cap:$337.31K

Valuation Multiples (3)

P/B Ratio:0.06x
P/S Ratio:0.01x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$1.44M

Price Action & Momentum (1)

% of 52-Week High:17.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-68.5%
Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-3.3%

Margin Analysis (3)

Operating Margin Ttm:-35.1%
Net Margin Ttm:-34.4%
Ebitda Margin:-33.8%

TTM Performance (2)

Operating Margin Ttm:-35.1%
Net Margin Ttm:-34.4%

Yield Metrics (2)

Earnings Yield:-$5.75K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:90.5%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):15.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.18x
Quick Ratio:1.08x
Cash Ratio:0.44x

Leverage Analysis (3)

Debt To Equity Ttm:0.97x
Debt-to-Equity Ratio:0.97x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-94.57x
Times Interest Earned:-94.57

Capital Structure (4)

Working Capital:1,894,000.00
Cash And Cash Equivalents:4,659,000.00
Long Term Debt:$2.41M
Net Debt:-$1.78M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $46.17M
Linear Growth: 15.7%
📊 Click to view full BFRIW Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$16.19M

Bottom Line Performance (3)

-$15.89M
Income Before Tax:-$15.84M
Ebitda Ttm:-15,599,000.00

Operating Expenses (5)

Operating Expenses:52,740,000.00
R And D Expense:2,990,000.00
Sga Expense:39,192,000.00
Income Tax Expense:$69.00K
Interest Expense:120,000.00

Expense Ratios (3)

R And D To Revenue Percentage:24.9%
Sga To Revenue Percentage:326.5%
Ebitda Margin:-33.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$24.06M
Current Assets:$12.44M
Ppe Net:2,139,000.00
Goodwill:0.00
Intangible Assets:$2.57M

Liability Structure (4)

Total Liabilities:18,108,000.00
Current Liabilities:10,541,000.00
Long Term Debt:$2.41M
Short Term Debt:$472.00K

Equity & Capital (3)

Equity:$5.96M
Retained Earnings:-$133.30M
Common Stock:70,000,000.00

Working Capital Items (3)

Accounts Receivable:5,545,000.00
Inventory:1,097,000.00
Accounts Payable:500,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:342,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$9.31M-$9.32M

Investment Activities (2)

Investing Cash Flow:-$5.00K
Capital Expenditures Ttm:4,000.00

Financing Activities (3)

Financing Cash Flow:$2.35M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:7,662,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:593,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.50
-$1.50
Earnings Per Share Ttm:-$1.23

Revenue & Cash Per Share (2)

Sales Per Share Ttm:3.57
Operating Cash Flow Per Share:-$1.03

Book Value & Capital (2)

Book Value Per Share:$0.46
Cash Per Share:0.36

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.99x
Working Capital Turnover Ttm:24.38x

Receivables Management (2)

Receivables Turnover Ttm:8.33x
Days Sales Outstanding Ttm:43.83

Inventory Management (2)

Inventory Turnover Ttm:42.09x
Days Inventory Outstanding Ttm:8.67

Payables & Cash Cycle (2)

Days Payable Outstanding:3.95
Cash Conversion Cycle:48.55
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$9.32M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-3.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):15.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-27.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:BFRIW
Company Name:Biofrontera Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:12.92M
Shares Outstanding Basic:12.92M
Shares Outstanding Diluted:12.92M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 16:40:36 UTC
Data Timestamp:2026-08-26T16:40:36.750178
Scroll to Top